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Two strains of Haemophilus in£uenzae have been designated
for quality control of antimicrobial susceptibility tests. For
each antimicrobial agent, the expected range of MICs or zone
diameters has been de¢ned for tests that are performed accord-
ing to the method of the National Committee for Clinical
Laboratory Standards (NCCLS). H. in£uenzaeATCC 49247 is
a b-lactamase-negative, ampicillin-resistant strain that pro-
vides on-scale MICs for many b-lactam antimicrobial agents.
However, tests of that control strain against some cephem
drugs have proven to be too variable to be useful for quality
control purposes. A second ampicillin-susceptible strain ofH.
in£uenzae (ATCC 49766) has been subsequently selected for
monitoring tests of those problematic drugs [1,2]. The latter
control strain is very susceptible to many b-lactam drugs, and
MICs are likely to be below the range of concentrations nor-
mally tested. For that reason, the alternative control strain (H.
in£uenzae ATCC 49766) is used only when the other control
strain (ATCC 49247) demonstrates excessive inter- and intra-
laboratory variability.
In 1991, multi-laboratory studies were carried out in order
to evaluate both control strains of H. in£uenzae against a vari-
ety of antimicrobial agents. Broth microdilution tests with
two carbapenems (imipenem and meropenem) were included
[1]. For testing meropenem, H. in£uenzae ATCC 49766 was
preferred, becauseMICs were muchmore reproducible. How-
ever, when imipenem was tested, the two control strains
showed nearly identical precision.The NCCLS subcommittee
reviewed these data and recommended the use ofH. in£uenzae
ATCC 49247 for both carbapenems.
In 1997, we were asked to study another carbapenem, erta-
penem (MK-0826), and this provided the opportunity to revi-
sit the question of quality control for tests of carbapenems in
HTM broth. A 10-laboratory study was coordinated in order
to document the results of replicate tests of ertapenem serially
diluted in ¢ve di¡erent lots of HTM broth; the control agent
(imipenem) was diluted in one lot of HTMbroth.The ¢ve lots
of HTM broth gave essentially the same results with ertape-
nem.This exercise generated 500 MICs of ertapenem and 100
MICs of imipenem from the10 laboratories.
Table1 combines previously published MIC data [1] that
were generated in 1991with those recorded in 1997, in order to
show the overall distribution of MICs recorded for three car-
bapenems. With the b-lactamase-negative, ampicillin-resis-
tant H. in£uenzae strain (ATCC 49247), MICs of ertapenem
were much too variable to permit de¢nition of a useful quality
control range, but the alternative control strain (ATCC 49766)
displayed much greater precision. In 1998, the NCCLS sub-
committee of antimicrobial susceptibility tests approved con-
trol limits of MIC 0.016^0.06mg/L for H. in£uenzae ATCC
49766, and that control rangewill be included in the appropri-
ate tables now that the drug has been assigned a generic name.
At the same time, MIC ranges for imipenem and meropenem
againstH. in£uenzaeATCC 49766 were also approved [3], and
the previously approved [4] limits for H. in£uenzae ATCC
49247 were removed from the tables.The information inTable
1showswhy that changewas made.
The lack of precision of broth microdilution tests of H.
in£uenzaeATCC 49247 may be attributed to a number of vari-
ables.We ¢nd no evidence that lot-to-lot variation in HTM
broth is a signi¢cant variable in these studies. Minor di¡er-
ences in the actual inoculum density are likely to be more
important. The alternative control strain is presumably less
sensitive to small changes in the inoculum. Subjectivity
involved in selecting the MIC endpoints may be another vari-
able that causes inconsistencies between readers.
The disk di¡usion test on HTM agar did not appear to be
a¡ected by these considerations, and either control strain ofH.
in£uenzae could be used. We recently provided carbapenem
disks to 30 di¡erent laboratories and asked them to test both
control strains on 20 separate days using HTM agar that was
available from their local provider. The overall range of zone
diameters that were recorded by this experiment was analyzed
by using the median statistic of Gavan et al [5] in order to cal-
culate quality control ranges for both control strains tested
against three carbapenems (Table 2).The current NCCLS con-
trol limits for carbapenem disk tests are supported by these
newdata, although the ranges might be adjusted by1or 2mm.
For all three drugs, H. in£uenzae ATCC 49247 is preferred
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because the zones are 3^5mm smaller and there is no advan-
tage to using themore susceptible control strain.
When the b-lactamase-negative, ampicillin-resistant strain
ofH. in£uenzae (ATCC 49247) is being tested, MICs of mero-
penem and ertapenem tend to display marked variability
between laboratories, whereas disk di¡usion test results are
much more consistent. For broth microdilution tests of carba-
penems, the ampicillin-susceptible strain of H. in£uenzae
(ATCC 49766) is preferred because of better inter- and intra-
laboratory precision.
Table 1 Broth microdilution MICs with two control strains of Haemophilus in¯uenzae tested against three carbapenems in two multi-labora-
tory collaborative studies done in 1991 and 1997a




(1991 and 1997 study)
Meropenem
(1991 Study)
MIC (mg/L) ATCC 49247b ATCC 49766 ATCC 49247 ATCC 49766 ATCC 49247 ATCC 49766
8.0 55
4.0 163
2.0 154 1 15c
1.0 25 87 85 6
0.5 41 92 118 25
0.25 38 1 37 17 44
0.12 19 1 8 5 25 1
0.06 5 109 9 114
0.03 377 1 10
0.016 9
0.008 3
Total no. 500 500 225 225 125 125
aFive laboratories participated in the 1991 study [1] and 10 contributed to the 1997 study. bBold type encompasses the control limits that
have been approved for each strain [3,4]; MIC limits could not be de®ned for H. In¯uenzae ATCC 49247 against ertapenem. cMIC> 1.0 mg/L
(>highest concentration tested); all 15 results were reported by one of ®ve laboratories.
Table 2 Disk diffusion susceptibility testsa with two control strains of Haemophilus in¯uenzae and three carbapenem disks as performed in
30 laboratories













ATCC 49247 21±29 20±28 24 92.4 585
ATCC 49766 23±31 27 92.7 600
Meropenem
ATCC 49247 20±28 22±28 25 91.8 583
ATCC 49766 26±34 30 91.8 597
Ertapenem
ATCC 49247 20±28 24 92.1 564
ATCC 49766 27±33 25±33 29 91.3 576
aResults expressed as the diameter of the zone of inhibition around each disk. bControl limits listed by the NCCLS [3] or tentative limits for
ertapenem. cQuality control limits calculated by the statistical method of Gavan et al [5]. dPercentage of zones within the calculated quality
control ranges. eTests with ATCC 49247 represent only 29 laboratories: for each carbapenem, a dif ferent laboratory reported very aberrant
results and all of their zones were excluded for these calculations. The calculated quality control ranges would not be altered if these data
had been included, but the percentage of zones within that range would be reduced somewhat.
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